All six of the SMARC genes, identified as being ITRs of MYCN’s genomic targets (ChIP-seq), were able to segregate neuroblastoma patients by outcome, according to the level of SMARC gene expression in tumours (Figure 1C and Supplementary Figure 1A). This evidence concerns the gene MYCN and neuroblastoma.